

# Daniel Podzamczar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1000438/publications.pdf>

Version: 2024-02-01

60  
papers

2,778  
citations

430874

18  
h-index

175258

52  
g-index

64  
all docs

64  
docs citations

64  
times ranked

2826  
citing authors

#	ARTICLE	IF	CITATIONS
1	Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , .	3.0	1
2	Detecting anal human papillomavirus infection in men who have sex with men living with HIV: implications of assay variability. <i>Sexually Transmitted Infections</i> , 2022, , sextrans-2021-055303.	1.9	0
3	Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naïve Adults Living With HIVâ€”1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). <i>Clinical Infectious Diseases</i> , 2021, 73, e1991-e1999.	5.8	10
4	No Changes in Human Immunodeficiency Virus (HIV) Suppression and Inflammatory Markers in Cerebrospinal Fluid in Patients Randomly Switched to Dolutegravir Plus Lamivudine (Spanish HIV/AIDS) Tj ETQq0 0 0.0gBT /Overlock 10 T		
5	Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). , 2021, 9, e001664.		11
6	Comparison of two sample collection devices for anal cytology in HIVâ€”positive men who have sex with men: Cytology brush and Dacron swab. <i>Cytopathology</i> , 2021, 32, 646-653.	0.7	1
7	Do All Integrase Strand Transfer Inhibitors Have the Same Lipid Profile? Review of Randomised Controlled Trials in NaÃ¬ve and Switch Scenarios in HIV-Infected Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 3456.	2.4	13
8	Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab439.	0.9	19
9	Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial. <i>Lancet HIV,the</i> , 2021, 8, e463-e473.	4.7	13
10	Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy. <i>Biochemical Pharmacology</i> , 2021, 192, 114666.	4.4	8
11	Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients. <i>Aids</i> , 2020, 34, 707-718.	2.2	30
12	Total and Unbound Bictegravir Concentrations and Viral Suppression in Cerebrospinal Fluid of Human Immunodeficiency Virus-Infected Patients (Spanish HIV/AIDS Research Network, PreEC/RIS 56). <i>Journal of Infectious Diseases</i> , 2020, 221, 1425-1428.	4.0	11
13	Clinical and pathological features of Kaposi sarcoma herpesvirus-associated inflammatory cytokine syndrome. <i>Aids</i> , 2020, 34, 2097-2101.	2.2	5
14	Lipids, biomarkers, and subclinical atherosclerosis in treatment-naïve HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study. <i>PLoS ONE</i> , 2020, 15, e0237739.	2.5	10
15	Acute inflammatory demyelinating polyneuropathy following interruption of antiretroviral treatment and HIV rebound. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1356-1357.	3.0	5
16	Measurement of total and unbound bictegravir concentrations in plasma and cerebrospinal fluid by UHPLC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 185, 113250.	2.8	12
17	Immediate Versus Deferred Switching From a Boosted Protease Inhibitorâ€”based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age â‰¥50 Years: Final 96-Week Results of the NEAT022 Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 597-606.	5.8	34
18	Efficacy and safety of dolutegravirâ€”rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. <i>Lancet HIV,the</i> , 2019, 6, e576-e587.	4.7	82

#	ARTICLE	IF	CITATIONS
19	Lack of benefit with omega-3 fatty acid supplementation in HIV patients: A randomized pilot study. HIV Research and Clinical Practice, 2019, 20, 99-105.	1.1	0
20	Switching strategies in the recent era of antiretroviral therapy. Expert Review of Clinical Pharmacology, 2019, 12, 235-247.	3.1	9
21	Changes in Body Fat Distribution in Antiretroviral-Naive HIV-Positive Individuals Initiating Current ART Regimens. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 900-905.	3.6	4
22	Long-term efficacy and safety of nevirapine-containing regimens in virologically suppressed patients: a 17-year follow up. HIV Research and Clinical Practice, 2019, 20, 151-155.	1.1	1
23	Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research) Tj ETQq1 1 0.784314 rgBT /Overlo	1.1	1
24	Costâ€ effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 16-20.	0.5	6
25	Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV,the, 2018, 5, e357-e365.	4.7	115
26	HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and Î±4Î²7 on CD4 T-Cells Prior Therapy Initiation. Frontiers in Immunology, 2018, 9, 1673.	4.8	7
27	Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice. AIDS Research and Human Retroviruses, 2017, 33, 29-32.	1.1	5
28	Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy. HIV Clinical Trials, 2017, 18, 49-53.	2.0	0
29	Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV. Expert Review of Anti-Infective Therapy, 2017, 15, 195-209.	4.4	22
30	Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet, The, 2017, 390, 2063-2072.	13.7	253
31	SÃfilis atÃpica extracutÃnea en pacientes con infecciÃn por VIH. Medicina ClÃnica, 2017, 149, 488-492.	0.6	0
32	Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet, The, 2017, 390, 1499-1510.	13.7	391
33	Pharmacokinetic analysis of nevirapine extended release 400Ãmg once daily vs nevirapine immediate release 200Ãmg twice daily formulation in treatment-naÃve patients with HIV-1 infection. HIV Clinical Trials, 2017, 18, 189-195.	2.0	3
34	Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection. Clinical Infectious Diseases, 2016, 62, 1578-1585.	5.8	5
35	Effectiveness and safety of an abacavir/lamivudineÃ+rÃrilpivirine regimen for the treatment of HIV-1 infection in naive patients. Journal of Antimicrobial Chemotherapy, 2016, 71, 3510-3514.	3.0	7
36	Dual antiretroviral therapy: finding a place in the battle. Lancet HIV,the, 2016, 3, e335-e336.	4.7	2

#	ARTICLE	IF	CITATIONS
37	Randomized trial of a multidisciplinary lifestyle intervention in HIV-infected patients with moderate-high cardiovascular risk. <i>Atherosclerosis</i> , 2016, 246, 301-308.	0.8	18
38	Prediction of higher cost of antiretroviral therapy (ART) according to clinical complexity. A validated clinical index. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 149-158.	0.5	3
39	Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 361-371.	0.5	10
40	Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1139-1145.	3.0	21
41	Differential Body Composition Effects of Protease Inhibitors Recommended for Initial Treatment of HIV Infection: A Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2015, 60, 811-820.	5.8	26
42	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 515-519.	2.1	190
43	Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1513-1516.	3.0	9
44	The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial. <i>Clinical Infectious Diseases</i> , 2015, 61, 403-408.	5.8	100
45	Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. <i>Lancet, The</i> , 2015, 385, 2606-2615.	13.7	521
46	Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline status. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, dkv272.	3.0	2
47	Prevalence of methicillin-resistant <i>Staphylococcus aureus</i> colonization in HIV-infected patients in Barcelona, Spain: a cross-sectional study. <i>BMC Infectious Diseases</i> , 2015, 15, 243.	2.9	13
48	Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC. <i>Journal of the International AIDS Society</i> , 2014, 17, 19550.	3.0	6
49	Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 70, 1130-8.	3.0	18
50	Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. <i>Lancet, The</i> , 2013, 381, 735-743.	13.7	455
51	Lipid metabolism and cardiovascular risk in HIV infection: new perspectives and the role of nevirapine. <i>AIDS Reviews</i> , 2013, 15, 195-203.	1.0	6
52	LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy. <i>Atherosclerosis</i> , 2012, 225, 200-207.	0.8	30
53	Switching to Raltegravir in Virologically Suppressed in HIV-1-Infected Patients: A Retrospective, Multicenter, Descriptive Study. <i>Current HIV Research</i> , 2012, 10, 673-678.	0.5	2
54	How Much Fat Loss Is Needed for Lipoatrophy to Become Clinically Evident?. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 563-567.	1.1	24

#	ARTICLE	IF	CITATIONS
55	Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2009, 50, 390-396.	2.1	19
56	Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. <i>Antiviral Therapy</i> , 2009, 14, 195-201.	1.0	51
57	A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). <i>Antiviral Therapy</i> , 2002, 7, 81-90.	1.0	7
58	A Randomized Clinical Trial Comparing Nelfinavir Or Nevirapine Associated to Zidovudine/Lamivudine in HIV-Infected Naive Patients (The Combine Study). <i>Antiviral Therapy</i> , 2002, 7, 81-90.	1.0	109
59	Hepatic and Pulmonary Pneumocystosis During Primary Prophylaxis for <i>Pneumocystis carinii</i> Pneumonia with Dapsone/Pyrimethamine. <i>Clinical Infectious Diseases</i> , 1993, 16, 171-171.	5.8	9
60	Doravirine Concentrations and HIV-1 RNA in the Genital Fluids of Virologically Suppressed Adults Switching to Doravirine plus Emtricitabine/Tenofovir Alafenamide. <i>Clinical Infectious Diseases</i> , 0, , .	5.8	1